Shopping Cart
Remove All
Your shopping cart is currently empty
Atoltivimab (REGN3470), also known as maftivimab/odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $247 | 2-4 weeks | 2-4 weeks | |
| 5 mg | $647 | 2-4 weeks | 2-4 weeks | |
| 10 mg | $987 | 2-4 weeks | 2-4 weeks |
| Description | Atoltivimab (REGN3470), also known as maftivimab/odesivimab (Inmazeb), represents the first monoclonal antibody approved by the Food and Drug Administration (FDA) to combat Zaire ebolavirus (EBOV) infection [1]. |
| Reactivity | Virus |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2135632-29-8 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.